HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers

This phase I study evaluated the feasibility of expanding HER-2/neu (HER2) vaccine-primed peripheral blood T-cells ex vivo and assessed the safety of T-cell infusions. Eight patients with HER2(+) treatment refractory metastatic cancers were enrolled. T-cells could be expanded to predefined parameter...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Disis, Mary L., Dang, Yushe, Coveler, Andrew L., Marzbani, Edmond, Kou, Zhong C., Childs, Jennifer S., Fintak, Patricia, Higgins, Doreen M., Reichow, Jessica, Waisman, James, Salazar, Lupe G.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2013
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3945106/
https://ncbi.nlm.nih.gov/pubmed/24162107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-013-1489-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars